Search

Researchers at Peking Union Medical College Hospital conducted a bibliometric analysis of research on medullary thyroid carcinoma (MTC) from 2000 to 2022. The study found a gradual increase in MTC-related literature over the past two decades, with the United States leading in publications. Key research areas include treatment, diagnosis, inhibitors, and exploring the pathogenesis of MTC. This information provides valuable insights into the current state and future trends in MTC research. [Extracted from the article]

Researchers from Ohio State University conducted a study on Medullary Thyroid Cancer (MTC) and identified CAPN1 as a key regulator of NF1 and RET fueled growth in MTC cells. The study found that CAPN1 inhibitors reduced MTC cell growth and synergized with existing therapies like vandetanib and selpercatinib. The research suggests that combinatorial therapies involving CAPN1 inhibitors and existing treatments show maximal efficacy in MTC cells. [Extracted from the article]

A study conducted at the University of Catania in Italy focused on Medullary Thyroid Cancer (MTC) in pediatric/adolescent carriers of the RET mutation. The research aimed to evaluate the genotype/phenotype correlation and outcomes in 23 patients under 19 years old who underwent thyroidectomy. The study found that genetic counseling and RET screening are crucial for first-degree relatives of patients with Multiple Endocrine Neoplasia type 2 syndrome (MEN2) to prevent the onset of MTC. Surgery for prophylactic purposes is recommended to reduce the risk of persistent or recurrent disease in pediatric/adolescent patients. [Extracted from the article]

A recent study conducted at the IRCCS Regina Elena National Cancer Institute in Rome, Italy, focused on the treatment outcomes and toxicities of multiple tyrosine kinase inhibitors (TKIs) for metastatic medullary thyroid cancer (MTC). The study included five patients with advanced MTC who were treated with at least two different TKIs, such as vandetanib, cabozantinib, and selpercatinib. The results showed that three patients achieved a partial response, while two patients experienced disease stability. The study emphasized the importance of an individualized approach to managing MTC, considering both treatment responses and potential toxicities to minimize treatment withdrawal. [Extracted from the article]

Researchers at the University of Texas MD Anderson Cancer Center conducted a study on the efficacy and safety of selective RET inhibitors in patients with advanced hereditary medullary thyroid carcinoma (MTC). The study included 23 patients with distant metastases, with most patients showing a partial response to treatment. The researchers found that the duration of response and adverse event profile were similar to sporadic MTC, indicating that selective RET inhibitors are safe and effective for patients with advanced hereditary MTC. [Extracted from the article]

A study conducted at Stanford University examined the impact of social vulnerability and demographics on outcomes in pediatric medullary thyroid cancer. The research found that Asian American/Pacific Islander patients and male patients may have poorer survival rates in pediatric medullary thyroid cancer. The study concluded that further research is needed to better understand the underlying factors influencing these outcomes. The findings were published in the International Journal of Pediatric Otorhinolaryngology and have been peer-reviewed. [Extracted from the article]

Boston University researchers have discovered a rare complication of systemic calcitonin amyloidosis causing nephrotic syndrome in a 65-year-old woman with metastatic medullary thyroid cancer. The case highlights the importance of considering nephrotic syndrome as a potential complication in patients with long-standing calcitonin elevation and characteristic symptoms. This research sheds light on the link between medullary thyroid cancer and systemic calcitonin amyloidosis, emphasizing the need for awareness and further study in this area. [Extracted from the article]

Researchers at Aga Khan University Hospital in Karachi, Pakistan, have published a case report on a woman with medullary thyroid cancer (MTC) in the background of a non-neoplastic toxic nodular goiter. The study highlights the importance of considering MTC as a potential diagnosis even in cases of hyperfunctioning nodular goiter and emphasizes the need for close follow-up of thyroid nodules, especially in patients with other primary malignancies. The researchers suggest measuring calcitonin levels in the workup of thyroid nodules in select cases to aid in early detection and management. [Extracted from the article]

A recent study conducted at Tulane University analyzed data on medullary thyroid cancer, specifically focusing on the optimal surgical approach for localized T1 medullary thyroid cancer. The research found that limited thyroidectomy, such as lobectomy or subtotal thyroidectomy, achieved comparable long-term survival to total thyroidectomy for early localized medullary thyroid cancer. The study suggests that selective use of limited thyroidectomy may be reasonable for low-risk T1N0/1M0 medullary thyroid cancer patients, while delayed surgery was associated with worse survival outcomes. The findings highlight the importance of personalized surgical approaches in the treatment of medullary thyroid cancer. [Extracted from the article]

The article discusses the risk of medullary thyroid cancer (MTC) and all-cause mortality in individuals with MEN2A-causing RET variants. A study of over 500,000 individuals from the UK and US found that these variants were predominantly of moderate risk and carried a lower MTC risk compared to clinically ascertained cases. Most variant carriers did not undergo thyroidectomy, and their mortality rates were similar to non-carriers. This research fills a knowledge gap and can aid in clinical decision-making regarding these genetic variants. [Extracted from the article]

Researchers from the National Institutes of Health (NIH) in Bethesda, Maryland, have conducted a study on the prognostic role of tumor volume doubling time (TVDT) in metastatic medullary thyroid cancer (MTC). The study included 51 patients with metastatic MTC and found that a TVDT of less than 1 year was associated with a higher risk of death from MTC. The research concluded that TVDT measurements from baseline and follow-up scans can be used as predictors of mortality from MTC. [Extracted from the article]

A recent study conducted by researchers at Universidade Federal de Sao Paulo focused on medullary thyroid cancer (MTC) and its resistance to treatment. The study identified cancer stem cell subpopulations within MTC cell lines and highlighted the role of DLK1 in enhancing the stemness phenotype, which could have implications for MTC progression and resistance. The findings provide valuable insights into potential therapeutic strategies for MTC. [Extracted from the article]

A recent study conducted at Tata Memorial Hospital Annexe in Mumbai, India, explored the use of a fibroblast activation protein inhibitor (FAPI)-based PET/CT imaging technique for medullary thyroid carcinoma (MTC). The research highlighted the potential of Ga-68-DOTA-FAPI-04 PET/CT in visualizing metastatic lesions with enhanced efficacy compared to other imaging methods. This study provides valuable insights into the variable tracer avidity and interlesional heterogeneity in MTC, offering new avenues for systemic treatments with fewer adverse effects. For more information, readers can refer to the article published in Clinical Nuclear Medicine. [Extracted from the article]

A recent study conducted by the National Institute of Diabetes and Digestive and Kidney Diseases focused on the prognostic role of tumor volume doubling time (TVDT) in metastatic medullary thyroid cancer (MTC). The study included 51 patients with metastatic MTC and found that a TVDT of less than one year was associated with a higher risk of death. The research concluded that TVDT can be used as a predictor of mortality from MTC, based on three baseline and three most recent scans. [Extracted from the article]

Researchers at the University of the Witwatersrand in South Africa have highlighted the challenges of managing Medullary Thyroid Carcinoma (MTC), a rare and aggressive form of thyroid cancer. They emphasize the need for personalized care due to the complexities of MTC and propose the integration of Holomics and Artificial Intelligence (AI) to enhance diagnostic processes and treatment plans. This innovative approach aims to improve global collaboration, equitable healthcare solutions, and ultimately transform the landscape of MTC treatment, aligning with the United Nations Sustainable Development Goal 3. [Extracted from the article]

A recent study from Emory University examined adherence to American Thyroid Association guidelines for medullary thyroid cancer (MTC) treatment. The research found that improved adherence to these guidelines may lead to better overall survival rates for patients with MTC. Factors associated with discordant treatment included gender, age, facility type, and proximity to treatment center. The study analyzed data from 2009 to 2015 and concluded that adherence to guidelines could positively impact patient outcomes. [Extracted from the article]

A recent study conducted by researchers at Tianjin Medical University General Hospital in China focuses on the management of medullary thyroid cancer using carcinoembryonic antigen (CEA) and calcitonin (Ctn) as biomarkers. The study emphasizes the importance of understanding and interpreting the variations in CEA and Ctn levels during the perioperative period for accurate diagnosis, treatment decisions, and prognosis of MTC. The researchers recommend follow-up diagnostic and treatment protocols to address potential pitfalls associated with the use of these biomarkers. For more information, the full article can be accessed for free at the Frontiers in Endocrinology website. [Extracted from the article]

Researchers at Hacettepe University School of Medicine have developed a new method, lymph node ACTH washout, to identify the source of ACTH production in a case of metastatic medullary thyroid carcinoma. This method was used on a 23-year-old male with Cushing's syndrome resulting from medullary thyroid cancer, leading to a diagnosis and subsequent treatment. The study highlights the potential effectiveness of lymph node ACTH washout as a diagnostic tool in cases of ACTH-dependent Cushing syndrome. [Extracted from the article]

The article discusses a case study from Rutgers University on metastatic medullary thyroid carcinoma presenting as an incidental posterior mediastinal mass. The research emphasizes the importance of testing for calcitonin in masses with neuroendocrine features to enable earlier detection of MTC and improve prognosis. This study highlights the significance of thorough testing for accurate diagnosis and treatment of rare neuroendocrine tumors like MTC. [Extracted from the article]

A recent study on medullary thyroid cancer conducted at the Affiliated Hospital of Nanjing University of Chinese Medicine in China highlights the challenges posed by this rare but aggressive form of thyroid malignancy. The research focuses on the molecular genetics of medullary thyroid cancer, particularly the role of the RET gene and the RAS gene family, offering insights into potential therapeutic targets and novel biomarkers. The study emphasizes the importance of precision therapies and the need for further research in this field to improve clinical practice and patient outcomes. [Extracted from the article]

A recent report from researchers at the Cancer Hospital in Beijing, China, highlights the use of a new imaging technique called Ga-68-TCR-FAPI PET-CT for detecting medullary thyroid carcinoma (MTC). The study compared the effectiveness of Ga-68-TCR-FAPI PET-CT with the currently approved F-18-FDG PET-CT in detecting MTC lesions. The results showed that Ga-68-TCR-FAPI PET-CT had a significantly higher detection rate and diagnostic accuracy compared to F-18-FDG PET-CT. This new imaging technique could improve the management and treatment decisions for MTC patients. [Extracted from the article]

A recent study conducted at Zhejiang Cancer Hospital focused on medullary thyroid cancer (MTC), a rare type of thyroid malignancy. The study found that MTC can be hereditary or sporadic, with different genetic mutations present in each case. Surgery is the standard treatment for early-stage MTC, while chemotherapy has shown limited effectiveness for metastatic MTC. However, targeted therapies for the RET gene have shown promise in increasing progression-free survival for patients with advanced MTC. The study also highlighted the need for further research on drug resistance and the development of novel therapeutic approaches. [Extracted from the article]

A recent study conducted at the Memorial Sloan-Kettering Cancer Center has found that the protein SEZ6 is highly expressed in medullary thyroid carcinoma (MTC), a type of thyroid cancer. SEZ6 has also been found in small cell lung carcinoma (SCLC) and is being targeted by a novel antibody drug conjugate called ABBV-011, which is currently in clinical trials for treating SCLC and neuroendocrine neoplasms, including MTC. The study suggests that SEZ6 could serve as a biomarker for MTC and that SEZ6-targeted therapy shows promise as a targeted treatment for MTC, even in cases without specific genetic mutations. [Extracted from the article]

A recent report from SRM Medical College Hospital and Research Centre in Tamil Nadu, India, discusses a case of medullary thyroid cancer. The patient, a 64-year-old male with uncontrolled type 2 diabetes mellitus and peripheral vascular disease, presented with a swelling on the right side of his neck. The swelling had slowly progressed over the past five years and was accompanied by palpable lymph nodes. Blood investigations revealed a reduced hemoglobin level, but thyroid function tests were normal. This case highlights the importance of considering thyroid carcinoma in patients with palpable lymph nodes. [Extracted from the article]

Recent findings from the University of Rochester provide new insights into medullary thyroid cancer (MTC). MTC is a rare primary neuroendocrine thyroid carcinoma that is distinct from other thyroid or neuroendocrine cancers. Most cases of MTC are sporadic, but it exhibits a high degree of heritability. The primary oncogenic drivers of MTC are RET mutations, and advances in molecular profiling have revealed druggable alterations. Surgery at an early stage is the only chance for a cure, but many patients present with or develop metastases. Biomarkers such as C-cell-specific calcitonin trajectory and structural doubling times are critical for prognosis and treatment decisions. Recent advances in active surveillance, regionally directed therapies, and systemic therapy with multi-kinase and RET-specific inhibitors have significantly improved outcomes for patients with MTC. [Extracted from the article]

A recent study conducted at the Cancer Hospital examined the survival rates of patients with medullary thyroid carcinoma (MTC) who did not achieve a biochemical cure after surgery. The study found that patients with high postoperative 1-month calcitonin (Ct) levels had a greater risk of mortality. Additionally, targeted therapy did not improve the overall survival of MTC patients with distant metastasis. These findings suggest that patients who do not achieve biochemical remission after surgery may be at an increased risk of death, and targeted therapy may not be effective in prolonging survival in certain cases. [Extracted from the article]

A recent report from the University of Colorado discusses new findings on medullary thyroid cancer (MTC), a hereditary cancer syndrome caused by germline-activating pathogenic variants in the RET proto-oncogene. The report focuses on the specific RET germline heterozygous variant K666N, which has been described in very few families. The researchers highlight the need for further understanding of the pathogenicity of this variant and the appropriate screening and treatment for asymptomatic carriers. The report includes a case study of a patient with the RET K666N variant who experienced cardiogenic shock and multi-organ failure. [Extracted from the article]

A study presented at the Annual Meeting of The European Association for the Study of Diabetes reveals that tirzepatide (TZP), a medication used to manage blood sugar levels and weight loss in individuals with type 2 diabetes (T2D), has a reassuring safety profile. The study compared TZP to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and found that TZP had similar gastrointestinal tolerability without an increased risk of pancreatitis, diabetic retinopathy, and medullary thyroid cancer. However, the study is limited by its observational nature and non-randomized comparisons, so caution should be exercised in interpreting the results. [Extracted from the article]

A recent bibliometric study conducted by researchers at the University of British Columbia focused on Medullary Thyroid Cancer (MTC). The study analyzed the most-cited publications in MTC research and highlighted the historical developments in this field. The analysis revealed a gradual increase in the number of publications on MTC over the years, with a focus on the genetic basis for MTC, targeted therapy, and guidelines. The study concluded that bibliometric analysis can help identify research frontiers in MTC. This research has been peer-reviewed and can be found in The American Journal of Surgery. [Extracted from the article]

A recent study conducted by researchers at the University of Catania in Italy explored the role of pre-operative calcitonin and CEA levels in predicting the extent of lymph node metastases in patients with medullary thyroid cancer (MTC). The study analyzed 87 MTC patients and found that higher levels of calcitonin and CEA were associated with a greater number of lymph node metastases. The researchers concluded that pre-operative serum calcitonin and CEA levels could help guide surgical decisions and determine the extent of surgery for MTC patients. This study provides valuable insights for clinicians treating MTC and may contribute to improved patient outcomes. [Extracted from the article]

A recent report from Yashoda Hospital discusses the rare occurrence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) in the same patient. The report describes the case of a 36-year-old male who presented with symptoms of headache, palpitations, and abdominal pain. After evaluation, the patient was found to have bilateral pheochromocytoma and MTC, as well as a RET proto-oncogene germline mutation. The patient underwent bilateral adrenalectomy and total thyroidectomy, and genetic analysis revealed a high-risk RET mutation. The report emphasizes the importance of early identification through genetic screening and prophylactic total thyroidectomy to prevent complications of aggressive MTC. [Extracted from the article]

A recent study conducted by researchers at Yonsei University College of Medicine in Seoul, South Korea, compared the diagnostic performance of preoperative calcitonin and procalcitonin tests for medullary thyroid cancer (MTC). MTC is a type of thyroid cancer with a relatively poor prognosis. The study found that both calcitonin and procalcitonin showed similar diagnostic utility for MTC, with high sensitivity and specificity. Depending on the patient's clinical status and laboratory environment, these tests can be used as complementary methods for detecting MTC. [Extracted from the article]

The article presents new findings from the University of Medicine and Pharmacy "Victor Babes" Timisoara on medullary thyroid carcinoma (MTC) in patients with Graves' disease. Topics discussed include the increased incidence of thyroid malignancies in Graves' disease patients, the case series of three women with MTC, and the recommendation for integrating calcitonin testing into standard diagnostic protocols.

The article focuses on a patent application submitted for a novel cancer treatment involving GFR Alpha-4 chimeric antigen receptors. Topics include the increasing incidence of medullary thyroid carcinoma (MTC), the role of GFRa4 as a target for MTC diagnosis and therapy, and the development of new antibodies and chimeric antigen receptors to improve treatment efficacy.

The article from the University of Texas MD Anderson Cancer Center explores the Medullary Thyroid Cancer Collaborative Registry (MTCCoRe) and its effectiveness in representing the real-world population of medullary thyroid cancer patients. Topics discussed include differences in patient demographics and clinical characteristics compared to population-based registries, variations in treatment modalities, and the need for improved inclusion of underrepresented groups in future studies.

A clinical trial has been launched to compare the diagnostic effects of two PET/CT scans, 68Ga-MGS5 and 68Ga-DOTATATE, on patients with medullary thyroid carcinoma (MTC). The trial aims to determine the effectiveness of these scans in detecting primary foci, lymph node metastasis, and distant metastasis of MTC, as well as their impact on the clinical staging of the disease. The study will enroll 20 patients and is being conducted at the First Hospital of Fujian Medical University in China. The trial is currently recruiting participants and is expected to be completed by July 2025. [Extracted from the article]

A recent study conducted at Radboud University Medical Center in the Netherlands investigated the use of digoxin to reinduce radioiodine uptake in patients with metastasized non-medullary thyroid carcinoma (NMTC) that is refractory to radioactive iodine (RAI). The study included eight patients who were treated with digoxin for three weeks, and their RAI uptake was compared before and after treatment. However, the results showed that digoxin treatment did not reinduce RAI uptake in these patients. This study highlights the challenges in optimizing studies aimed at restoring RAI uptake and its therapeutic efficacy through drug repurposing. [Extracted from the article]

A recent study conducted at Shanghai Sixth People's Hospital investigated the impact of primary tumor resection (PTR) on patients with distant metastasis medullary thyroid carcinoma (DMMTC). The study aimed to assess the benefits of PTR and identify optimal surgical indications. The research found that PTR significantly improves prognosis in selected DMMTC patients, with significant advantages in overall survival (OS) and disease-specific survival (DSS) for the surgical group. However, the decision to undergo PTR in other patients should be based on a comprehensive assessment of the disease, surgeon's experience, and family discussions for potential survival benefits. [Extracted from the article]

A clinical trial, NCT06530316, is currently underway in China to evaluate the effectiveness and safety of RET inhibitors as neoadjuvant therapy for locally advanced RET-altered thyroid cancer. The trial involves administering RET inhibitors to patients in a real-world setting, followed by surgical treatment for those eligible. The study aims to assess various outcomes, including resection rate, objective response rate, disease control rate, time to objective response, progression-free survival, overall survival, and adverse events. The document provides information about an FDA-regulated device product without disclosing the collaborators or investigators. The keywords associated with this article cover topics such as pharmaceuticals, surgery, genetics, clinical research, thyroid neoplasms, drugs and therapies, health and medicine, neoadjuvant therapy, combined modality therapy, clinical trials and studies, medullary thyroid carcinoma, and oncology - medullary thyroid cancer. [Extracted from the article]

A study conducted at the Hospital of the University of Pennsylvania examined the presentation and treatment of medullary thyroid cancer (MTC) and found disparities based on sex and race/ethnicity. The study analyzed data from the National Cancer Database and found that male and non-White patients with MTC were more likely to present with advanced disease. Additionally, Black patients were less likely to undergo guideline-concordant surgery. These findings highlight the need for further research and interventions to address these disparities in the management of MTC. [Extracted from the article]

A recent study conducted by researchers at the University of Sydney explores the molecular biology of medullary thyroid carcinoma (MTC) and its interaction with the immune system. The study found that MTC is primarily driven by specific pathogenic variants, resulting in a low tumor mutational burden and a limited number of tumor-associated neoantigens. This suggests that immunotherapy may not be effective in treating MTC. The study also highlights the efficacy of targeted tyrosine kinase inhibitors (TKIs) in comparison to multi-kinase inhibitors (MKIs) for MTC treatment. However, the use of TKIs may promote the survival of resistant tumor cells. [Extracted from the article]

A recent study conducted by Martin Luther-University Halle-Wittenberg in Germany compared the oncological features of sporadic and hereditary pediatric medullary thyroid cancer (MTC). The study found that sporadic MTC is extremely rare in infancy and childhood, and infrequent in adolescence. The researchers analyzed data from 1252 patients with MTC, of which only 4 pediatric patients had sporadic MTC. These patients had larger thyroid tumors and were more comparable to carriers of high-risk mutations in terms of extrathyroid extension and nodal metastases. The study concluded that sporadic MTC, although rare, presents with similar characteristics to hereditary MTC at diagnosis. [Extracted from the article]

A recent study conducted at the Medical University of Vienna in Austria examined the use of [18F]F-DOPA PET/CT in the diagnosis and prognosis of medullary thyroid cancer (MTC). The study analyzed data from 109 MTC patients who underwent [18F]F-DOPA PET/CT scans between 2008 and 2023. The results showed that [18F]F-DOPA PET/CT had a high diagnostic accuracy for detecting tumor lesions, with a sensitivity of 65% and a specificity of 99%. The study also found that certain PET/CT parameters, such as SUVmean and MTV, were associated with overall survival in MTC patients. Overall, the study concluded that [18F]F-DOPA PET/CT is a valuable tool for both diagnosis and prognosis assessment in MTC patients. [Extracted from the article]

A recent study conducted by researchers at Maltepe University in Istanbul, Turkey, has found that elevated levels of procalcitonin (PCT) can occur in both bacterial infections and medullary thyroid carcinoma (MTC). MTC is a rare form of thyroid cancer that originates from parafollicular cells. The study highlights the importance of PCT and carcinoembryonic antigen (CEA) as biomarkers for diagnosing and monitoring MTC, as elevated levels of these markers can indicate the presence of the disease. Integrating PCT and CEA measurements into routine clinical practice can improve detection, provide insights into therapeutic responses, and aid in the management of MTC. [Extracted from the article]

Researchers at Ordine Mauriziano Hospital in Turin, Italy have conducted a study on medullary thyroid carcinoma (MTC), a type of thyroid cancer. The study aimed to determine if preoperative neck ultrasound combined with pathological data could impact the outcome of MTC. The researchers analyzed data from MTC patients diagnosed between 2000 and 2021 and found that disease-free survival was significantly different based on staging, capsular status, and neck ultrasound. They concluded that preoperative neck ultrasound can help predict the outcome of MTC. This information is important for individuals researching MTC and its prognosis. [Extracted from the article]

A recent study conducted by researchers at the University Health Center examined the long-term survival outcomes of systemic therapy in patients with isolated and mixed medullary thyroid cancer (MTC). The study found that there was no significant difference in overall survival between isolated and mixed MTC. However, systemic therapy was associated with improved survival in isolated MTC but not in the mixed subtype. These findings suggest the need for further investigation and may inform tailored management strategies for mixed MTC. The study was published in the journal Heliyon. [Extracted from the article]